NCT05293665View on ClinicalTrials.gov

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

PHASE3UnknownINTERVENTIONAL
Enrollment

944

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

September 30, 2023

Conditions
COVID-19 Vaccines
Interventions
BIOLOGICAL

UB-612

UB-612 (100µg), 0.5mL suspension, intramuscular injection

BIOLOGICAL

BNT162b2 vaccine

BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection

BIOLOGICAL

ChAdOx1-S vaccine

ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection

BIOLOGICAL

Sinopharm BIBP

Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection

Trial Locations (7)

78521

PanAmerican Clinical Research, Brownsville

Unknown

Cevaxin David, David

Cevaxin 24 de Dieciembre, Panama City

Cevaxin The Panama Clinic, Panama City

Health Index Multispecialty, Bacoor

Iloilo Doctors Hospital, Iloilo City

St Pauls Hospital Iloilo City, Iloilo City

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Vaxxinity, Inc.

INDUSTRY

NCT05293665 - Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine | Biotech Hunter | Biotech Hunter